greeksoup/ stock research
Stock research / United States / AZN / Year to 31 December 2025

AstraZeneca PLC (AZN) annual results, year to 31 December 2025: revenue USD 58,739 million, from the 20-F

AstraZeneca PLC files a 20-F with the SEC once a year, in US dollars. In the year to 31 December 2025 it reported revenue of USD 58,739 million, up 8.6% on the year before. Its profit attributable to shareholders was USD 10,225 million, up 45.3%, and diluted earnings per share USD 6.54.

Revenue
USD 58,739 million
+8.6% on the year
FY2018FY2025
Operating margin
23.4%
18.5% a year earlier
FY2018FY2025
Net income
USD 10,225 million
+45.3% on the year
FY2018FY2025
Diluted EPS
USD 6.54
+45.3% on the year
FY2018FY2025

this yearthe year beforeIn US dollars as filed. Hover a bar for its figure.

Income statement (profit and loss)

Year toDec 2024Dec 2025
Revenue54,07358,739
Cost of sales10,20710,633
Gross profit43,86648,106
Research and development13,58314,232
Selling, general and administrative19,97719,933
Operating profit10,00313,743
Finance costs1,7421,694
Profit before tax8,69112,402
Income tax1,6502,169
Profit for the year7,04110,233
Profit attributable to shareholders7,03510,225
Filing20-F20-F
USD million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated.
Year toDec 2024Dec 2025
Diluted EPS4.506.54
Basic EPS4.546.60
Filing20-F20-F

USD per ordinary share, as filed.

Cash flow

Year toDec 2024Dec 2025
Cash from operations11,86114,575
Purchase of property, plant and equipment1,9242,810
Free cash flow9,93711,765
Cash from investing-7,980-6,808
Cash from financing-3,996-7,544
Buybacks81.0521
Dividends paid4,6294,971
Filing20-F20-F

USD million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.

Balance sheet

Year toDec 2024Dec 2025
Funded by
Equity attributable to shareholders40,78648,667
Non-controlling interests85.052.0
Borrowings, as filed28,84327,819
Lease liabilities1,4521,803
Other liabilities32,86935,733
Total equity and liabilities104,035114,074
Owned
Property, plant and equipment10,25212,962
Goodwill21,02521,242
Other intangible assets37,17737,846
Cash and cash equivalents5,4885,711
Trade and other receivables12,97215,177
Inventories5,2886,557
Other assets11,83314,579
Total assets104,035114,074
Filing20-F20-F

USD million, at each fiscal year end.

Ratios on the filed lines

Year toDec 2024Dec 2025
Gross margin81.1%81.9%
Operating margin18.5%23.4%
Net margin13.0%17.4%
Free cash flow margin18.4%20.0%
Return on year-end equity17.2%21.0%
Effective tax rate19.0%17.5%
Filing20-F20-F

Arithmetic on the filed lines of the same year.

20-F for the year to 31 December 2025, filed 24 February 2026: the filing. The figures are in US dollars as filed.